Germany’s G-BA blocks added-benefit status for Alzheimer’s drug Lecanemab
New clinical data has severely undercut the promise of antibody-based Alzheimer’s therapies, showing that these drugs offer minimal improvement in cognitive function while increasing the risk of brain swelling. The findings emerge as a critical blow to a treatment path that the European Commission first approved in 2025, specifically targeting the underlying disease processes in … Weiterlesen …